UNIQUE EXPERTISE
Headquartered in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using our unique expertise and population resources, deCODE has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer.
UNIQUE CAPABILITIES
We operate the most productive human gene discovery engine in the world, employing our discoveries to identify genetic variations associated with human disease.
OUR PUBLICATIONS
We regularly publish our discoveries in major, peer-reviewed journals, enabling others to further validate and expand upon our findings.
NEWS
deCODE Successfully Completes Phase I Clinical Program for DG041 for the Treatment of Peripheral Artery Disease
February 21, 2006 deCODE genetics (Nasdaq:DCGN) today announced top-line results from Phase I clinical studies of DG041, the company's developmental compound for the treatment of peripheral artery disease (PAD). The company has completed the Phase I studies of DG041...
deCODE Expands Cancer Program through Acquisition of Icelandic Cancer Research Group
January 18, 2006 deCODE genetics (Nasdaq:DCGN) today announced its acquisition of privately-held Icelandic cancer research firm Urdur, Verdandi Skuld (UVS). The acquisition enables deCODE to broaden and enhance its cancer program by applying the company's unique gene...
Award by the American Society of Human Genetics
At its Annual meeting in October 2017 in Orlando, the American Society of Human Genetics (ASHG), presented Dr. Kári Stefánsson, founder and CEO of deCODE genetics, with the William Allan Award. The award, the top prize given by the society, recognizes a scientist for substantial and far-reaching scientific contributions to human genetics. The ASHG has distributed video footage from the award ceremony. The introduction is given by Professor Mark Daly of Harvard University.